Last updated: 11/07/2018 20:01:57
A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban
Trial description: A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
L. Bergmann, D. Browning, I. Schrijver, N. Stepner, J.Wilson. Zyban: Real life effectiveness in clinical practice. Proceedings of the 4th European Meeting of Society for Research on Nicotine and Tobacco: Improving Knowledge and Treatments of Nicotine Addiction. Section A3 (Treatment: Bupropion): Abstract #4, 2002.
P.Selby, B.Brands, N.Stepner. Re-treatment with Zyban SR: 52 week follow-up of Canadian multicenter trial. Conference Proceedings of the 3rd American Meeting of Society for Research on Nicotine and Tobacco: Improving Knowledge and Treatments of Nicotine Addiction, 2003.
P.Selby, G. Brosky, R. Baker, M. Lertzman, P. Dakin, J. Roberts. Zyban is effective in the re-treatment of relapsed adult smokers. Presented 7th Annual Meeting of Society for Research on Nicotine and Tobacco; Seattle, Washington (2001).
P.Selby, G. Brosky, R. Baker, M. Lertzman, P. Dakin, J. Roberts. Zyban is effective in the re-treatment of relapsed adult smokers. Proceedings of the 3rd European Meeting of Society for Research on Nicotine and Tobacco; Paris, France (2001).
P.Selby, M.Ainslie. N. Stepner, J. Roberts. Sustained-release bupropion (Zyban®) is effective in the re-treatment of relapsed adult smokers. Am J Res and Crit Care Med 167 (7): A47, 2003.
Medical condition
Smoking Cessation
Product
bupropion
Collaborators
Not applicable
Study date(s)
January 2000 to June 2001
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-04-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website